珍寶島(603567.SH)三個品種調出新版醫保目錄
格隆匯8月21日丨珍寶島(603567.SH)公佈,2019年8月20日,國家醫保局人力資源社會保障部發布了關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄》的通知(醫保發[2019]46號),並要求遵照執行。
公司在2019年新版醫保目錄共24個品種,其中有9個品種不受醫保支付限制。與2017年醫保目錄相比,有10個品種未發生變化,有17個品種有所調整。
調出醫保的共三個品種,其中複方氨酚烷胺膠囊2018年至2019年一季度未銷售,另外兩個品種(即注射用骨肽、骨肽注射液)2018年及2019年一季度毛利額分別為3.58億元、1.15億元,佔比分別為18%、20%。
隨着2019年《國家醫保目錄》的發佈,公司注射用骨肽由僅限工傷保險報銷變更為調出國家醫保目錄;注射用血塞通、舒血寧注射液等產品醫保支付範圍做了相應的限制調整。新版目錄的執行將對公司現有品種銷售業績產生一定的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.